9906 (9906) Fair Value & Analysis

Healthcare · Market cap HK$936M

9 9906 9906 · HK

PriceHK$1.56

Fair ValueHK$1.14

Upside-26.9%

Quality63/100

Watch 9906 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$0.8600 – HK$1.43

Fair value as of: Jul 3, 2026

From 24 valuation models · updated today

Price vs Fair Value (12 months)

12‑month range HK$1.50 – HK$1.75 · fair‑value band HK$0.8600 – HK$1.43 · the HK$1.56 price screens above the HK$1.14 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

9906 (9906) currently trades at HK$1.56, while our model-based Fair Value estimate is HK$1.14 — implying the stock looks roughly 26.9% overvalued today. We read business quality at 63/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 9906 generated revenue of HK$700M at a net margin of 1.5%. Revenue declined 16.5% year over year. It earns a return on equity of 1.9%. The balance sheet holds a net cash position of HK$82.5M. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) HK$700M

Revenue growth (YoY) -16.5%

Net margin 1.5%

Return on equity 1.9%

Free cash flow HK$31.2M FY2024

P/E ratio 78.0

More key figures

Operating margin 1.0%

EPS growth (YoY) -13.6%

Net cash HK$82.5M FY2024

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2020 – FY2024 · reported fiscal years

9906 reported revenue of HK$769M in FY2024 versus HK$524M in FY2020, a compound +10.1%/yr. Reported net income was HK$31.2M in FY2024, compounding +9.3%/yr from FY2020.

Revenue +10.1%/yr

FY20 HK$524M

FY21 HK$607M

FY22 HK$728M

FY23 HK$761M

FY24 HK$769M

Net income +9.3%/yr

FY20 HK$21.8M

FY21 HK$36.6M

FY22 HK$48.9M

FY23 HK$38.3M

FY24 HK$31.2M

Is 9906 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$95.75	R$123.65	+29%
Fresenius SE FSNUY	$11.30	$8.61	-24%
5225 5225	8.67 MYR	3.08 MYR	-64%
IHHHF IHHHF	$1.71	$0.7400	-57%
Tenet Healthcare Corporation THC	$162.06	$282.55	+74%
Rede D'Or São Luiz S.A RDOR3	R$32.76	R$30.33	-7%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 9906 (9906) undervalued?

As of Jul 3, 2026, our model estimates a fair value of HK$1.14 versus a price of HK$1.56 — about −27% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 9906?

Our model-based fair value for 9906 is HK$1.14 (as of Jul 3, 2026), built from audited fundamentals. The current price is HK$1.56.

What is the quality score of 9906?

9906 has a Quality Score of 63/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 9906 (9906)?

9906 reported trailing-twelve-month revenue of about HK$700M (latest available figure, as of Jul 3, 2026).

What is the net profit margin of 9906?

The net profit margin of 9906 is about 1.5%, meaning it keeps roughly 1.5% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.